PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients
| Autor: | Mesa, R., Hudgens, S., Floden, L., Palmer, J., Gupta, V., McLornan, D.P., McMullin, M.F., Kiladjian, J.J., Foltz, L., Platzbecker, U., Fox, M.L., Mead, A.J., Ross, D.M., Oh, S.T., Perkins, A., Leahy, M.F., Deheshi, S., Donahue, R., Klencke, B.J., Verstovsek, S. |
|---|---|
| Zdroj: | In Value in Health June 2021 24 Supplement 1:S22-S22 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect